Prognostic value of the aggregate index of systemic inflammation in predicting in-hospital adverse outcomes among patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention Authors: Erkan Kahraman, Kemal Emrecan Parsova, Furkan Durak, Ayca Gumusdag, Hakan Iskender, Bilal Cakir, Yalcin Velibey Published: 2026 ABSTRACT ObjectivesInflammation plays a pivotal role in the initiation and progression of atherosclerosis and acute coronary syndromes. The Aggregate Index of Systemic Inflammation (AISI), a novel biomarker derived from neutrophil, monocyte, platelet, and lymphocyte counts, reflects the systemic inflammatory response. Although AISI has demonstrated prognostic value in various cardiovascular settings, its utility in its association with in-hospital adverse outcomes among patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) remains unclear. This study aimed to evaluate whether AISI reflects systemic inflammatory burden and its association with in-hospital adverse outcomes in STEMI patients undergoing primary PCI.Materials and methodsThis retrospective, single-center study included 2,678 consecutive STEMI patients who underwent primary PCI. AISI was calculated as (neutrophil × monocyte × platelet) / lymphocyte, and patients were stratified into high and low AISI groups according to the median value. The primary outcomes were in-hospital mortality and major adverse cardiac and cerebrovascular events (MACCE). Secondary endpoints included arrhythmic complications, acute stent thrombosis, and ischemic stroke.ResultsPatients with high AISI were older, had higher rates of diabetes and hypertension, elevated glucose and creatinine, and lower left ventricular ejection fraction. High AISI was associated with mortality and MACCE in univariate analyses, whereas continuous AISI showed only a statistically significant but clinically modest association after multivariable adjustment when expressed per 100-unit increase. These findings indicate that AISI has limited standalone prognostic value and should be interpreted as an adjunctive inflammatory marker. Elevated AISI showed an independent association with ischemic stroke (adjusted OR = 4.77, 95% CI 1.02–22.30, p = 0.047); however, this finding should be interpreted cautiously given the low number of events and wide confidence intervals. ROC analysis showed moderate discriminative performance for in-hospital mortality (AUC = 0.64), MACCE (AUC = 0.60), and ischemic stroke (AUC = 0.70).ConclusionAISI is a simple, cost-effective inflammatory marker that may aid in risk stratification for in-hospital adverse and cerebrovascular outcomes in STEMI patients undergoing primary PCI. Background Atherosclerosis is now recognized as a chronic, immune-inflammatory disease rather than a simple lipid storage disorder. Activated leukocytes, platelets, and endothelial cells contribute to vascular dysfunction, plaque formation, and subsequent rupture, all of which culminate in thrombotic events and myocardial infarction [1]. Inflammatory cytokines and chemokines regulate the recruitment of neutrophils and monocytes to the vascular intima, while systemic inflammatory activation promotes oxidative stress and platelet aggregation [2]. This inflammatory cascade not only underlies the pathophysiology of atherosclerotic cardiovascular disease but also plays a pivotal role in acute coronary syndromes (ACS), where a heightened inflammatory response can worsen ischemic injury and reperfusion outcomes. Given the central role of inflammation in coronary artery disease (CAD), several hematologic indices derived from routine complete blood counts, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), have been proposed as cost-effective and readily accessible biomarkers for systemic inflammation [3, 4]. Elevated levels of these indices have been associated with disease severity, left ventricular dysfunction, and major adverse cardiovascular and cerebrovascular events (MACCE). However, most of these indices reflect limited aspects of the inflammatory response, failing to integrate both myeloid and thrombocytic activity. To address this limitation, the aggregate index of systemic inflammation (AISI) was introduced as a novel composite biomarker that combines neutrophil, monocyte, platelet, and lymphocyte counts. By incorporating multiple inflammatory cell lines, AISI is hypothesized to more accurately represent the overall systemic inflammatory burden. Recent studies have demonstrated its prognostic value in several clinical contexts, including carotid artery stenosis, abdominal aortic calcification, hypertension, and acute heart failure [5–7]. In coronary artery disease, high AISI levels have been associated with increased long-term mortality and adverse cardiovascular outcomes after percutaneous coronary intervention (PCI) [8]. Furthermore, elevated AISI has been identified as being independently associated with in-stent restenosis in patients treated with drug-eluting stents, underscoring the potential link between systemic inflammation and post-intervention complications [9]. The inflammatory response is particularly pronounced in patients presenting with ST-segment elevation myocardial infarction (STEMI), as both ischemic necrosis and subsequent reperfusion elicit an intense systemic immune reaction. Despite significant advances in reperfusion therapy and antithrombotic strategies, STEMI remains associated with substantial in-hospital morbidity and mortality. According to the most recent guidelines, early identification of high-risk individuals using inflammatory and hematologic biomarkers may enhance prognostication and individualized management [10]. Although growing evidence supports the prognostic relevance of AISI in various cardiovascular disorders, data specifically addressing its role in STEMI patients undergoing primary PCI remain limited. Previous studies have predominantly focused on long-term outcomes in chronic CAD or mixed ACS populations, leaving the short-term prognostic implications of AISI largely unexplored. Considering the critical impact of inflammation on early post-intervention outcomes, including in-hospital mortality, arrhythmias, and MACCE, there is a compelling rationale to evaluate AISI as an integrative biomarker for acute prognostication. Therefore, this study aimed to investigate the prognostic value of the AISI in its association with in-hospital adverse outcomes among patients with STEMI undergoing primary PCI. By assessing the association between admission AISI levels and early clinical outcomes, this work seeks to provide novel insights into inflammation-based risk stratification and to expand the utility of AISI as a practical biomarker in contemporary STEMI management. Methods Study design and population This retrospective, single-center observational study included 2,678 consecutive patients diagnosed with STEMI who underwent primary PCI at a tertiary heart center between January 2019 and December 2024. All patients were admitted through the regional STEMI network and underwent urgent coronary angiography within 12 h of symptom onset. Patients who had received pre-hospital fibrinolytic therapy, were managed conservatively, underwent rescue PCI, or had missing hematologic or biochemical data were excluded from the analysis. Diagnostic criteria for STEMI Patients were diagnosed with STEMI if they presented with ischemic chest pain lasting > 30 min, accompanied by persistent ST-segment elevation or an ST-elevation equivalent pattern on the electrocardiogram (ECG) consistent with acute coronary artery occlusion. ST-segment elevation was defined as new elevation at the J-point in two contiguous leads with the following criteria: ≥2.5 mm in men < 40 years, ≥ 2.0 mm in men ≥ 40 years, or ≥ 1.5 mm in women in leads V2–V3, and/or ≥ 1.0 mm in other contiguous leads, in the absence of left ventricular hypertrophy or left bundle branch block. In patients with bundle branch block or paced rhythm, the diagnosis of STEMI was established based on ischemic symptoms together with elevated cardiac biomarkers indicating myocardial necrosis and electrocardiographic findings consistent with acute coronary syndrome, including Sgarbossa or modified Sgarbossa criteria when applicable, in accordance with current guideline recommendations [11]. Procedural and pharmacologic management All patients received a loading dose of acetylsalicylic acid (300 mg) and one of the following P2Y₁₂ inhibitors before PCI: clopidogrel (600 mg), prasugrel (60 mg), or ticagrelor (180 mg). Intravenous unfractionated heparin (70–100 U/kg) was administered prior to coronary instrumentation. The use of glycoprotein IIb/IIIa inhibitors was left to the operator’s discretion according to angiographic thrombus burden or no-reflow phenomena, in alignment with guideline-based institutional protocols. All PCI procedures were performed with contemporary drug-eluting stents using standard techniques [11]. The culprit lesion was identified based on clinical presentation, ECG findings, and angiographic appearance. Successful PCI was defined as final Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow in the infarct-related artery with < 20% residual stenosis after stenting. Unsuccessful PCI included final TIMI ≤ 2 flow, residual stenosis ≥ 30%, requirement for emergency coronary artery bypass grafting (CABG), or intraprocedural death [11]. Laboratory analysis Venous blood samples were collected upon admission before the PCI procedure. Complete blood count parameters and routine biochemistry were analyzed in the hospital’s central laboratory using standard automated methods. The AISI was calculated as follows: (neutrophil count × monocyte count × platelet count) / lymphocyte count. Patients were divided into two groups based on the median AISI value: high AISI and low AISI groups. The estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI formula. Chronic kidney disease (CKD) was defined as eGFR < 30 mL/min/1.73 m², and anemia was defined as hemoglobin < 12 g/dL on admission. Left ventricular ejection fraction (LVEF) was measured within the first 24 h after admission using transthoracic echocardiography. Study outcomes The primary adverse in-hospital outcomes were all-cause mortality and major adverse cardiac and cerebrovascular events (MACCE), defined as the composite of death, reinfarction, stroke, or urgent revascularization. Secondary endpoints included arrhythmic complications (sustained ventricular tachycardia or fibrillation, and atrial fibrillation), acute stent thrombosis confirmed angiographically, and in-hospital stroke. Ischemic stroke was defined as the sudden onset of a new focal neurological deficit lasting more than 24 h, confirmed by compatible findings on brain computed tomography or magnetic resonance imaging. Hemorrhagic strokes were excluded [12]. Stroke events were recorded during in-hospital follow-up and post-discharge clinical surveillance. Ventricular arrhythmias included sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) that occurred during or after the index primary PCI procedure and were confirmed by continuous cardiac monitoring or electrocardiographic documentation. Atrial fibrillation (AF) was defined as a new-onset irregular supraventricular tachyarrhythmia with absent P waves and variable R–R intervals, observed during or following PCI hospitalization [13]. Patients with pre-existing chronic AF were not classified as having post-PCI arrhythmic events. Major bleeding was defined according to the Bleeding Academic Research Consortium (BARC) criteria as type 3 or higher bleeding, including overt gastrointestinal, intracranial, or access-site bleeding resulting in a decrease in hemoglobin of ≥ 3 g/dL, transfusion of ≥ 2 units of blood, or bleeding requiring surgical intervention [14]. Minor bleeding events (BARC type 1–2) were not included in the primary endpoint analysis. Ethical considerations The study protocol was approved by the Institutional Ethics Committee of Istanbul Medipol University (Approval No. E-10840098-202.3.02-5847). Written informed consent was obtained from all participants at the time of enrollment in the original registry between 2019 and 2024. The present study represents a retrospective analysis of previously collected data, and the requirement for obtaining additional informed consent was waived by the Institutional Ethics Committee. Patient confidentiality was maintained throughout the study. The study was conducted in accordance with the principles of the Declaration of Helsinki. Statistical analysis All statistical analyses were performed using IBM SPSS Statistics version 26.0 (IBM Corp., Armonk, NY, USA). Continuous variables were assessed for normality using the Kolmogorov–Smirnov test. Normally distributed variables were expressed as mean ± standard deviation (SD) and compared using the independent-samples t-test, while non-normally distributed variables were expressed as median (interquartile range, IQR) and compared using the Mann–Whitney U-test. Categorical variables were presented as frequencies and percentages, and compared using the chi-square or Fisher’s exact test, as appropriate. Receiver operating characteristic (ROC) curve analysis was performed to determine the optimal cutoff value of the AISI for predicting in-hospital adverse outcomes, and the area under the curve (AUC) was calculated.ROC-derived optimal cut-off values were closely aligned with the median AISI level, supporting the median-based dichotomization and indicating that the study findings were not dependent on a specific threshold selection. AISI was primarily analyzed as a continuous variable in regression models to preserve statistical power and avoid information loss associated with dichotomization. The median-based categorization was used as a secondary approach to facilitate group comparisons and clinical interpretability. Variable selection for regression analyses was based on clinical relevance, biological plausibility, and statistical considerations to avoid model overfitting. Binary logistic regression analyses were performed separately for each clinical outcome. Independent predictors of in-hospital mortality, in-hospital MACCE, and ischemic stroke were evaluated using distinct multivariable logistic regression models. In addition, selected individual components of the composite endpoint were evaluated using separate regression models when the number of events allowed reliable multivariable analysis. Variables with p < 0.10 in univariate analysis and clinically relevant covariates were considered for inclusion in the multivariable models. This approach allowed evaluation of both crude (unadjusted) and adjusted associations between AISI and clinical outcomes. Multicollinearity among covariates included in the regression models was assessed using variance inflation factor (VIF) analysis. No significant multicollinearity was detected (all VIF values < 5). Continuous and dichotomized forms of AISI were evaluated in separate multivariable models to avoid collinearity, and were not included simultaneously in the same regression model. Odds ratios (ORs) and 95% confidence intervals (CIs) were reported. LVEF was entered into the regression models as a continuous variable. Kaplan–Meier survival curves were constructed to compare in-hospital mortality across AISI groups, and statistical differences were evaluated using the log-rank test. A two-tailed p value < 0.05 was considered statistically significant. Results A total of 2,678 patients with STEMI who underwent primary PCI were included in the study. The median admission AISI value was 697, and patients were stratified into low- and high-AISI groups accordingly. Baseline demographic, clinical, and laboratory characteristics are summarized in Table 1. Overall, demographic variables were largely comparable between groups. However, patients with high AISI exhibited a more pronounced inflammatory and adverse metabolic profile, characterized by elevated neutrophil, monocyte, and platelet counts with lower lymphocyte levels. They also demonstrated higher admission creatinine, blood urea nitrogen, and glucose levels, as well as reduced LVEF. Procedural success was lower (92.0% vs. 95.3%, p < 0.001), in the high-AISI group, and the incidence of MACCE was significantly higher (5.7% vs. 3.7%, p = 0.019). Although in-hospital mortality, and stroke were numerically increased in patients with elevated AISI (2.6% vs. 1.6%, p = 0.081 and 0.7% vs. 0.1%, p = 0.071, respectively), these differences did not reach statistical significance. Rates of stent thrombosis, major bleeding, and arrhythmic complications were comparable between groups. Table 1Baseline demographic, clinical, and laboratory characteristics according to AISI groupsOverall (n = 2678)Low (< 697) AISI (n = 1339)High (≥ 697) AISI (n = 1339)p valueAge (years)56.00 [49.00–65.00]57.00 [49.00–65.00]55.00 [48.00–65.00]0.088Male sex, n (%)2233 (83.4)1103 (82.5)1130 (84.3)0.239Hypertension, n (%)761 (30.3)375 (29.9)386 (30.8)0.704Diabetes mellitus, n (%)550 (21.6)276 (21.7)274 (21.4)0.931Current smoking, n (%)1046 (41.7)532 (42.5)514 (41.0)0.462Hyperlipidemia, n (%)670 (25.9)373 (28.8)297 (23.0)< 0.001eGFR < 30 mL/min/1.73m2, n (%)22 (0.8)11 (0.8)11 (0.8)1.000Anemia, n (%)394 (14.7)180 (13.5)214 (16.0)0.077Prior PCI, n (%)339 (12.7)170 (12.7)169 (12.6)0.977Prior CABG, n (%)72 (2.7)38 (2.8)34 (2.5)0.710COPD, n (%)25 (0.9)9 (0.7)16 (1.2)0.231Stroke history, n (%)35 (1.3)15 (1.1)20 (1.5)0.502Admission glucose (mg/dL)131.00 [111.00–171.00]128.00 [109.00–168.00]133.00 [113.00–173.00]0.003Creatinine (mg/dL)0.82 [0.72–1.00]0.80 [0.71–0.97]0.83 [0.73–1.00]0.012BUN (mg/dL)16.00 [13.00–19.00]15.00 [13.00–18.00]16.00 [13.00–20.00]< 0.001eGFR (mL/min/1.73 m²)95.40 [81.25–105.00]95.45 [82.00–104.70]95.20 [79.50–105.60]0.597Hemoglobin (g/dL)13.80 [12.70–14.80]13.80 [12.70–14.80]13.90 [12.70–14.90]0.614Platelet count (×10³/µL)231.00 [197.00–275.00]213.00 [181.00–245.00]252.00 [215.00–299.00]< 0.001Neutrophil (×10³/µL)8.90 [6.75–11.39]7.00 [5.50–8.60]11.09 [9.20–13.40]< 0.001Lymphocyte (×10³/µL)1.70 [1.20–2.32]2.00 [1.42–2.70]1.50 [1.10–2.00]< 0.001Monocyte (×10³/µL)0.60 [0.42–0.80]0.50 [0.40–0.70]0.70 [0.50–0.90]< 0.001AISI696.90 [394.02–1218.98]393.96 [258.74–532.62]1218.98 [893.48–1800.54]< 0.001LVEF (%)47.50 [40.00–55.00]50.00 [42.50–55.00]45.00 [40.00–52.50]< 0.001Successful PCI (TIMI 3), n (%)2507 (93.6)1275 (95.3)1232 (92.0)< 0.001Unsuccessful PCI (TIMI ≤ 2), n (%)171 (6.4)64 (4.7)107 (8.0)< 0.001Ischemic stroke, n (%)11 (0.4)2 (0.1)9 (0.7)0.071In-hospital mortality, n (%)56 (2.1)21 (1.6)35 (2.6)0.081Post-PCI AF, n (%)50 (1.9)23 (1.7)27 (2.0)0.676Post-PCI VT/VF, n (%)39 (1.5)15 (1.1)24 (1.8)0.200Acute stent thrombosis, n (%)38 (1.4)19 (1.4)19 (1.4)1.000MACCE, n (%)127 (4.7)50 (3.7)77 (5.7)0.019Major bleeding, n (%)10 (0.4)3 (0.2)7 (0.5)0.344Abbreviations: AISI aggregate index of systemic inflammation, eGFR estimated glomerular filtration rate, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, COPD chronic obstructive pulmonary disease, BUN blood urea nitrogen, LVEF left ventricular ejection fraction, TIMI thrombolysis in myocardial infarction, AF atrial fibrillation, VT ventricular tachycardia, VF ventricular fibrillation, MACCE major adverse cardiac and cerebrovascular events Table 1Baseline demographic, clinical, and laboratory characteristics according to AISI groupsOverall (n = 2678)Low (< 697) AISI (n = 1339)High (≥ 697) AISI (n = 1339)p valueAge (years)56.00 [49.00–65.00]57.00 [49.00–65.00]55.00 [48.00–65.00]0.088Male sex, n (%)2233 (83.4)1103 (82.5)1130 (84.3)0.239Hypertension, n (%)761 (30.3)375 (29.9)386 (30.8)0.704Diabetes mellitus, n (%)550 (21.6)276 (21.7)274 (21.4)0.931Current smoking, n (%)1046 (41.7)532 (42.5)514 (41.0)0.462Hyperlipidemia, n (%)670 (25.9)373 (28.8)297 (23.0)< 0.001eGFR < 30 mL/min/1.73m2, n (%)22 (0.8)11 (0.8)11 (0.8)1.000Anemia, n (%)394 (14.7)180 (13.5)214 (16.0)0.077Prior PCI, n (%)339 (12.7)170 (12.7)169 (12.6)0.977Prior CABG, n (%)72 (2.7)38 (2.8)34 (2.5)0.710COPD, n (%)25 (0.9)9 (0.7)16 (1.2)0.231Stroke history, n (%)35 (1.3)15 (1.1)20 (1.5)0.502Admission glucose (mg/dL)131.00 [111.00–171.00]128.00 [109.00–168.00]133.00 [113.00–173.00]0.003Creatinine (mg/dL)0.82 [0.72–1.00]0.80 [0.71–0.97]0.83 [0.73–1.00]0.012BUN (mg/dL)16.00 [13.00–19.00]15.00 [13.00–18.00]16.00 [13.00–20.00]< 0.001eGFR (mL/min/1.73 m²)95.40 [81.25–105.00]95.45 [82.00–104.70]95.20 [79.50–105.60]0.597Hemoglobin (g/dL)13.80 [12.70–14.80]13.80 [12.70–14.80]13.90 [12.70–14.90]0.614Platelet count (×10³/µL)231.00 [197.00–275.00]213.00 [181.00–245.00]252.00 [215.00–299.00]< 0.001Neutrophil (×10³/µL)8.90 [6.75–11.39]7.00 [5.50–8.60]11.09 [9.20–13.40]< 0.001Lymphocyte (×10³/µL)1.70 [1.20–2.32]2.00 [1.42–2.70]1.50 [1.10–2.00]< 0.001Monocyte (×10³/µL)0.60 [0.42–0.80]0.50 [0.40–0.70]0.70 [0.50–0.90]< 0.001AISI696.90 [394.02–1218.98]393.96 [258.74–532.62]1218.98 [893.48–1800.54]< 0.001LVEF (%)47.50 [40.00–55.00]50.00 [42.50–55.00]45.00 [40.00–52.50]< 0.001Successful PCI (TIMI 3), n (%)2507 (93.6)1275 (95.3)1232 (92.0)< 0.001Unsuccessful PCI (TIMI ≤ 2), n (%)171 (6.4)64 (4.7)107 (8.0)< 0.001Ischemic stroke, n (%)11 (0.4)2 (0.1)9 (0.7)0.071In-hospital mortality, n (%)56 (2.1)21 (1.6)35 (2.6)0.081Post-PCI AF, n (%)50 (1.9)23 (1.7)27 (2.0)0.676Post-PCI VT/VF, n (%)39 (1.5)15 (1.1)24 (1.8)0.200Acute stent thrombosis, n (%)38 (1.4)19 (1.4)19 (1.4)1.000MACCE, n (%)127 (4.7)50 (3.7)77 (5.7)0.019Major bleeding, n (%)10 (0.4)3 (0.2)7 (0.5)0.344Abbreviations: AISI aggregate index of systemic inflammation, eGFR estimated glomerular filtration rate, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, COPD chronic obstructive pulmonary disease, BUN blood urea nitrogen, LVEF left ventricular ejection fraction, TIMI thrombolysis in myocardial infarction, AF atrial fibrillation, VT ventricular tachycardia, VF ventricular fibrillation, MACCE major adverse cardiac and cerebrovascular events Baseline demographic, clinical, and laboratory characteristics according to AISI groups Abbreviations: AISI aggregate index of systemic inflammation, eGFR estimated glomerular filtration rate, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, COPD chronic obstructive pulmonary disease, BUN blood urea nitrogen, LVEF left ventricular ejection fraction, TIMI thrombolysis in myocardial infarction, AF atrial fibrillation, VT ventricular tachycardia, VF ventricular fibrillation, MACCE major adverse cardiac and cerebrovascular events The incidence of acute stent thrombosis (1.4%) in our cohort appears slightly higher than that reported in some contemporary PCI registries. However, our study exclusively included STEMI patients undergoing primary PCI, a setting characterized by high thrombus burden, intense inflammatory activation, hemodynamic instability, and frequent no-reflow, all of which are known risk factors for early thrombotic events. Thus, the observed rate likely reflects the high-risk, real-world nature of this population rather than procedural inadequacy. Similarly, the relatively elevated rate of unsuccessful PCI may be attributed to complex coronary anatomy, heavy thrombus burden, distal embolization, cardiogenic shock, and microvascular obstruction factors commonly encountered in acute STEMI. As a tertiary referral center within a regional STEMI network, our institution treats a substantial proportion of critically ill and late-presenting patients, which may further explain these findings. In-hospital mortality In univariate analysis (Table 2), age, male sex, hypertension, diabetes mellitus, hyperlipidemia, admission glucose, baseline creatinine, reduced LVEF, anemia, and continuous AISI were associated with in-hospital mortality. High AISI showed a trend toward increased mortality but did not reach statistical significance (OR = 1.681, 95%CI: 0.973–2.903, p = 0.063). After multivariable adjustment (Table 2), age, admission glucose, baseline creatinine, and reduced LVEF remained independently associated with in-hospital mortality. When evaluated as a continuous variable and expressed per 100-unit increase, AISI demonstrated a statistically significant but clinically modest association with in-hospital mortality after multivariable adjustment (adjusted OR = 1.013, 95% CI: 1.001–1.024, p = 0.041). Given the small magnitude of the effect estimate and the confidence interval approaching the null value, this association should be interpreted with caution and considered in conjunction with established clinical predictors. Table 2Univariate and multivariate logistic regression analysis for in-hospital mortalityCharacteristicUnivariate AnalysisMultivariate AnalysisOdds Ratio95% CI p Odds Ratio95% CI p Age (per 1-year increase)1.0811.056–1.106< 0.0011.0681.033–1.104< 0.001Male sex0.4480.251–0.7990.0071.5150.577–3.9780.399Hypertension1.7671.009–3.0960.0470.9040.404–2.0250.806Diabetes mellitus4.2332.448–7.322< 0.0011.1990.508–2.8340.678Hyperlipidemia0.2920.116–0.7380.0090.410.14–1.190.100Current smoking0.5760.314–1.0580.0750.980.42–2.260.960Admission glucose (per 10-mg/dL increase)1.0081.006–1.010< 0.0011.0061.003–1.009< 0.001Baseline creatinine (per 1-mg/dL increase)10.4456.156–17.725< 0.0015.0892.668–9.704< 0.001LVEF (per 1% increase)0.9040.879–0.929< 0.0010.9190.892–0.947< 0.001AISI (continuous, per 100-unit increase)1.0191.010–1.028< 0.0011.0131.001–1.0240.041Anemia2.3691.314–4.2740.0040.6520.247–1.7250.389High AISI1.6810.973–2.9030.0631.2960.621–2.7040.490Abbreviations: LVEF left ventricular ejection fraction, AISI aggregate index of systemic inflammation*Odds ratios for continuous variables are expressed per unit increase as follows: per 1-year increase in age, per 10-mg/dL increase in admission glucose, per 1-mg/dL increase in baseline creatinine, per 1% increase in LVEF, and per 100-unit increase in AISI Table 2Univariate and multivariate logistic regression analysis for in-hospital mortalityCharacteristicUnivariate AnalysisMultivariate AnalysisOdds Ratio95% CI p Odds Ratio95% CI p Age (per 1-year increase)1.0811.056–1.106< 0.0011.0681.033–1.104< 0.001Male sex0.4480.251–0.7990.0071.5150.577–3.9780.399Hypertension1.7671.009–3.0960.0470.9040.404–2.0250.806Diabetes mellitus4.2332.448–7.322< 0.0011.1990.508–2.8340.678Hyperlipidemia0.2920.116–0.7380.0090.410.14–1.190.100Current smoking0.5760.314–1.0580.0750.980.42–2.260.960Admission glucose (per 10-mg/dL increase)1.0081.006–1.010< 0.0011.0061.003–1.009< 0.001Baseline creatinine (per 1-mg/dL increase)10.4456.156–17.725< 0.0015.0892.668–9.704< 0.001LVEF (per 1% increase)0.9040.879–0.929< 0.0010.9190.892–0.947< 0.001AISI (continuous, per 100-unit increase)1.0191.010–1.028< 0.0011.0131.001–1.0240.041Anemia2.3691.314–4.2740.0040.6520.247–1.7250.389High AISI1.6810.973–2.9030.0631.2960.621–2.7040.490Abbreviations: LVEF left ventricular ejection fraction, AISI aggregate index of systemic inflammation*Odds ratios for continuous variables are expressed per unit increase as follows: per 1-year increase in age, per 10-mg/dL increase in admission glucose, per 1-mg/dL increase in baseline creatinine, per 1% increase in LVEF, and per 100-unit increase in AISI Univariate and multivariate logistic regression analysis for in-hospital mortality Abbreviations: LVEF left ventricular ejection fraction, AISI aggregate index of systemic inflammation *Odds ratios for continuous variables are expressed per unit increase as follows: per 1-year increase in age, per 10-mg/dL increase in admission glucose, per 1-mg/dL increase in baseline creatinine, per 1% increase in LVEF, and per 100-unit increase in AISI MACCE Variables associated with in-hospital MACCE are shown in Table 3. In univariate analysis, several clinical and laboratory parameters, including continuous AISI expressed per 100-unit increase (OR = 1.015, 95% CI: 1.007–1.023, p < 0.001) and categorical high AISI (OR = 1.568, 95% CI: 1.089–2.257, p = 0.016), were associated with in-hospital MACCE. Following multivariable adjustment, age, admission glucose, baseline creatinine, and reduced LVEF remained independently associated with in-hospital MACCE. When evaluated as a continuous variable and expressed per 100-unit increase, AISI also demonstrated a statistically significant but clinically modest association with in-hospital MACCE (adjusted OR = 1.012, 95% CI: 1.000–1.024, p = 0.047). Given the small magnitude of the effect estimate and the confidence interval approaching the null value, this association should be interpreted with caution and suggests limited standalone prognostic value. Table 3Univariate and multivariate logistic regression analysis for in-hospital MACCECharacteristicUnivariate AnalysisMultivariate AnalysisOdds Ratio95%CI p Odds Ratio95%CI p Age (per 1-year increase)1.0401.025–1.056< 0.0011.0261.007–1.0470.009Male sex0.5250.350–0.7890.0020.9590.538–1.7090.886Hypertension1.5071.026–2.2130.0371.0140.626–1.6430.954Diabetes mellitus2.6951.847–3.934< 0.0011.3270.775–2.2710.302Hyperlipidemia0.5530.339–0.9010.0170.6060.334–1.0990.099Current smoking0.8590.585–1.2620.439———Admission glucose (per 10-mg/dL increase)1.0061.004–1.007< 0.0011.0031.000–1.0050.035Baseline creatinine (per 1-mg/dL increase)5.4003.531–8.257< 0.0012.7861.689–4.594< 0.001LVEF (per 1% increase)0.9470.930–0.964< 0.0010.9600.941–0.979< 0.001AISI (continuous, per 100-unit increase)1.0151.007–1.023< 0.0011.0121.000–1.0240.047High AISI1.5681.089–2.2570.016———Anemia1.6921.132–2.5270.0101.1670.693–1.9650.562Abbreviations: LVEF left ventricular ejection fraction, AISI aggregate index of systemic inflammation*Odds ratios for continuous variables are expressed per unit increase as follows: per 1-year increase in age, per 10-mg/dL increase in admission glucose, per 1-mg/dL increase in baseline creatinine, per 1% increase in LVEF, and per 100-unit increase in AISI Table 3Univariate and multivariate logistic regression analysis for in-hospital MACCECharacteristicUnivariate AnalysisMultivariate AnalysisOdds Ratio95%CI p Odds Ratio95%CI p Age (per 1-year increase)1.0401.025–1.056< 0.0011.0261.007–1.0470.009Male sex0.5250.350–0.7890.0020.9590.538–1.7090.886Hypertension1.5071.026–2.2130.0371.0140.626–1.6430.954Diabetes mellitus2.6951.847–3.934< 0.0011.3270.775–2.2710.302Hyperlipidemia0.5530.339–0.9010.0170.6060.334–1.0990.099Current smoking0.8590.585–1.2620.439———Admission glucose (per 10-mg/dL increase)1.0061.004–1.007< 0.0011.0031.000–1.0050.035Baseline creatinine (per 1-mg/dL increase)5.4003.531–8.257< 0.0012.7861.689–4.594< 0.001LVEF (per 1% increase)0.9470.930–0.964< 0.0010.9600.941–0.979< 0.001AISI (continuous, per 100-unit increase)1.0151.007–1.023< 0.0011.0121.000–1.0240.047High AISI1.5681.089–2.2570.016———Anemia1.6921.132–2.5270.0101.1670.693–1.9650.562Abbreviations: LVEF left ventricular ejection fraction, AISI aggregate index of systemic inflammation*Odds ratios for continuous variables are expressed per unit increase as follows: per 1-year increase in age, per 10-mg/dL increase in admission glucose, per 1-mg/dL increase in baseline creatinine, per 1% increase in LVEF, and per 100-unit increase in AISI Univariate and multivariate logistic regression analysis for in-hospital MACCE Abbreviations: LVEF left ventricular ejection fraction, AISI aggregate index of systemic inflammation *Odds ratios for continuous variables are expressed per unit increase as follows: per 1-year increase in age, per 10-mg/dL increase in admission glucose, per 1-mg/dL increase in baseline creatinine, per 1% increase in LVEF, and per 100-unit increase in AISI Ischemic stroke A total of 11 ischemic stroke events occurred during in-hospital follow-up, corresponding to 0.4% of the overall cohort. Stroke events were observed in 2 patients in the low-AISI group and 9 patients in the high-AISI group, corresponding to event rates of 0.1% and 0.7%, respectively.Stroke events were infrequent in the study cohort. In univariate analysis (Table 4), male sex, diabetes mellitus, and admission glucose were significantly associated with ischemic stroke. Continuous AISI, when expressed per 100-unit increase, was not significantly associated with ischemic stroke (OR = 1.007, 95% CI: 0.997–1.016, p = 0.154), whereas high AISI showed a borderline association (OR = 4.534, 95% CI: 0.978–21.023, p = 0.053). In the multivariable categorical model, high AISI was associated with ischemic stroke (adjusted OR = 4.77, 95% CI: 1.02–22.30, p = 0.047). However, given the low number of stroke events, the wide confidence interval, and the absence of an independent association for continuous AISI, this finding should be interpreted with caution and considered hypothesis-generating. Table 4Univariate and multivariate logistic regression analysis for ischemic strokeCharacteristicUnivariate AnalysisMultivariate AnalysisOdds Ratio95%CI p Odds Ratio95%CI p Age (per 1-year increase)1.0250.976–1.0770.321———Male sex0.2370.072–0.7810.0180.3460.100–1.1920.093Hypertension1.9200.584–6.3100.283———Diabetes mellitus6.4391.878–22.0770.0033.6320.888–14.8580.073Hyperlipidemia1.0740.284–4.0620.916———Current smoking0.5220.138–1.9730.338———Admission glucose (per 10-mg/dL increase)1.0051.002–1.0080.0021.0040.999–1.0090.157Baseline creatinine (per 1-mg/dL increase)1.7130.369–7.9580.492———LVEF (per 1% increase)0.9590.906–1.0150.149———AISI (continuous, per 100-unit increase)1.0070.997–1.0160.154———Anemia0.3490.044–2.7990.322———High AISI4.5340.978–21.0230.0534.771.02–22.300.047Abbreviations: LVEF left ventricular ejection fraction, AISI aggregate index of systemic inflammation*Odds ratios for continuous variables are expressed per unit increase as follows: per 1-year increase in age, per 10-mg/dL increase in admission glucose, per 1-mg/dL increase in baseline creatinine, per 1% increase in LVEF, and per 100-unit increase in AISI Table 4Univariate and multivariate logistic regression analysis for ischemic strokeCharacteristicUnivariate AnalysisMultivariate AnalysisOdds Ratio95%CI p Odds Ratio95%CI p Age (per 1-year increase)1.0250.976–1.0770.321———Male sex0.2370.072–0.7810.0180.3460.100–1.1920.093Hypertension1.9200.584–6.3100.283———Diabetes mellitus6.4391.878–22.0770.0033.6320.888–14.8580.073Hyperlipidemia1.0740.284–4.0620.916———Current smoking0.5220.138–1.9730.338———Admission glucose (per 10-mg/dL increase)1.0051.002–1.0080.0021.0040.999–1.0090.157Baseline creatinine (per 1-mg/dL increase)1.7130.369–7.9580.492———LVEF (per 1% increase)0.9590.906–1.0150.149———AISI (continuous, per 100-unit increase)1.0070.997–1.0160.154———Anemia0.3490.044–2.7990.322———High AISI4.5340.978–21.0230.0534.771.02–22.300.047Abbreviations: LVEF left ventricular ejection fraction, AISI aggregate index of systemic inflammation*Odds ratios for continuous variables are expressed per unit increase as follows: per 1-year increase in age, per 10-mg/dL increase in admission glucose, per 1-mg/dL increase in baseline creatinine, per 1% increase in LVEF, and per 100-unit increase in AISI Univariate and multivariate logistic regression analysis for ischemic stroke Abbreviations: LVEF left ventricular ejection fraction, AISI aggregate index of systemic inflammation *Odds ratios for continuous variables are expressed per unit increase as follows: per 1-year increase in age, per 10-mg/dL increase in admission glucose, per 1-mg/dL increase in baseline creatinine, per 1% increase in LVEF, and per 100-unit increase in AISI ROC curve analyses ROC curve analyses (Fig. 1) demonstrated limited discriminative performance of AISI for in-hospital outcomes, with an AUC of 0.64 (95% CI: 0.553–0.723) for in-hospital mortality and 0.60 (95% CI: 0.542–0.649) for MACCE. These findings indicate that AISI alone has limited ability to discriminate patients at risk for these outcomes. For ischemic stroke, the AUC was 0.70 (95% CI: 0.517–0.880); however, this result should be interpreted cautiously because of the low number of stroke events and the wide confidence interval. Overall, the ROC findings do not support AISI as a standalone predictive tool but suggest that it may provide adjunctive information as part of a broader clinical risk assessment. Fig. 1ROC curves evaluating the discriminative performance of AISI for in-hospital mortality, MACCE, and stroke. Abbreviations: ROC-receiver operating characteristic; AISI-aggregate index of systemic inflammation; MACCE- major adverse cardiac and cerebrovascular events ROC curves evaluating the discriminative performance of AISI for in-hospital mortality, MACCE, and stroke. Abbreviations: ROC-receiver operating characteristic; AISI-aggregate index of systemic inflammation; MACCE- major adverse cardiac and cerebrovascular events Discussion In this retrospective study of 2,678 patients with STEMI undergoing primary PCI, we found that AISI was associated with an adverse clinical profile and worse in-hospital outcomes. Although high AISI values were related to increased rates of in-hospital mortality and MACCE in univariate analysis, these associations were attenuated after multivariable adjustment. Importantly, the attenuation of the association between AISI and major clinical outcomes after multivariable adjustment suggests that AISI primarily reflects the underlying inflammatory and metabolic milieu rather than acting as a strong independent determinant. This finding indicates that systemic inflammation operates as an upstream modifier interacting with established risk factors such as age, renal dysfunction, and left ventricular systolic function. The relationship between inflammation and atherosclerosis is well established, with inflammatory activation influencing every stage from plaque initiation to rupture and thrombosis [1, 2]. Neutrophils, monocytes, and platelets interact in a coordinated manner to promote endothelial injury, thrombus formation, and microvascular obstruction [15–17]. Neutrophil extracellular traps (NETs) further contribute to coagulation activation [18] and no-reflow phenomena after primary PCI [19]. In addition, cytokine-mediated neurohormonal activation promotes hyperglycemia and sympathetic stimulation, amplifying oxidative stress and myocardial oxygen demand [20, 21]. Within this framework, AISI integrates multiple inflammatory cell lines and may serve as a composite marker of thrombo-inflammatory burden, which explains its association with admission glucose, renal dysfunction, reduced LVEF, and procedural complexity. The attenuation of its independent effect after multivariable adjustment indicates that systemic inflammation likely operates as an upstream modulator interacting with established clinical risk factors rather than functioning as an isolated driver of mortality or MACCE. The observed association between high AISI and ischemic stroke should be interpreted with caution and regarded as hypothesis-generating rather than confirmatory. Systemic inflammation may contribute to cerebrovascular events through endothelial dysfunction, plaque destabilization, platelet activation, and thrombus propagation [22–25]. In this context, shared inflammatory and thrombotic mechanisms between coronary and cerebral vascular territories may support the concept of a cardiocerebral thrombo-inflammatory axis. Our findings are also consistent with prior observations showing associations between AISI and hypertension, coronary artery disease, heart failure, and post-PCI restenosis [6, 9]. However, in the present study, the stroke analysis was limited by the low number of events, wide confidence intervals, and the absence of an independent association for continuous AISI. Therefore, although our analysis specifically evaluated an exclusively STEMI population undergoing primary PCI and focused on short-term in-hospital outcomes, the observed stroke finding should not be interpreted as evidence that AISI is a reliable cerebrovascular predictor. Rather, it represents a potential signal that requires validation in larger prospective STEMI cohorts with sufficient cerebrovascular event numbers. From a clinical perspective, AISI has several practical advantages, as it can be easily calculated at admission using routinely available complete blood count parameters and may reflect the systemic thrombo-inflammatory burden in patients with STEMI. However, the ROC curve analyses demonstrated only limited discriminative performance for in-hospital mortality and MACCE, indicating that AISI alone is insufficient for clinically meaningful standalone risk prediction. This finding is consistent with the concept that inflammation-based hematologic indices capture only one component of the complex risk profile in acute STEMI, which is also influenced by age, renal function, glycometabolic status, left ventricular systolic function, angiographic complexity, and procedural factors. Although the AUC for ischemic stroke was numerically higher than those for mortality and MACCE, this estimate should be interpreted with particular caution because it was derived from a small number of events and was accompanied by a wide confidence interval. Therefore, the stroke ROC finding should not be regarded as evidence of reliable cerebrovascular predictive utility, but rather as a hypothesis-generating observation requiring validation in larger cohorts. Overall, AISI should be interpreted as an adjunctive biomarker of systemic inflammatory and thrombotic activation rather than as an independent prediction tool, and its potential value lies in providing additional biological context when considered alongside established clinical, laboratory, echocardiographic, and angiographic risk indicators. This study has several limitations. Its retrospective, single-center design precludes causal inference and may limit generalizability. AISI was measured only once upon admission, preventing assessment of temporal inflammatory dynamics during hospitalization. Serial measurements may provide more comprehensive prognostic information. Furthermore, comparisons with established inflammatory biomarkers such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), or systemic inflammation response index (SIRI) were not performed, limiting the ability to determine the relative or incremental value of AISI. In addition, long-term outcomes were not evaluated. Therefore, AISI should be interpreted as a complementary inflammatory marker rather than a superior alternative to established biomarkers. Prospective studies are warranted to determine the incremental prognostic utility of AISI and to validate its role beyond the acute phase. In conclusion, AISI reflects systemic inflammatory and thrombotic activation in patients with STEMI undergoing primary PCI. Although continuous AISI showed statistically significant but clinically modest associations with in-hospital mortality and MACCE, its standalone prognostic value appears limited, particularly in light of its limited discriminative performance in ROC analysis. The observed association between high AISI and ischemic stroke should be interpreted cautiously and considered hypothesis-generating, given the low number of events, wide confidence interval, and lack of an independent association for continuous AISI. Overall, AISI may provide adjunctive biological information during early risk stratification when interpreted together with established clinical, biochemical, echocardiographic, and angiographic risk factors; however, the present findings do not support its use as a standalone prognostic or predictive tool.